Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

20193,323 citationsJournal Articlebronze Open Access

Authors

Brian I. Rini · Cleveland Clinic

Elizabeth R. Plimack · Fox Chase Cancer Center

V.P. Stus · Ministry of Health

Rustem Gafanov · Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology

Robert D. Hawkins · The Christie NHS Foundation Trust

Dmitry Nosov · Central Clinical Hospital and Polyclinic

Frédéric Pouliot

Abstract

Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).

Topics & Keywords

Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers Renal and related cancers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 12, pp. 1116-1127

DOI: 10.1056/nejmoa1816714

Field-Weighted Citation Impact: 345.66